Advanced search
Publication Cover
Lung Cancer: Targets and Therapy Volume 6, 2015 - Issue
Submit an article Journal homepage
59
Views
2
CrossRef citations to date
0
Altmetric
Review

First-line treatment of advanced ALK-positive non-small-cell lung cancer

Shipra Gandhi1 Department of Internal Medicine, State University of New York
,
Hongbin Chen2 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
,
Yujie Zhao2 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
&
Grace K Dy2 Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USACorrespondence[email protected]
Pages 71-82 | Published online: 18 Sep 2015

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Abhay Singh & Hongbin Chen. (2020) Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors. Cancer Management and Research 12, pages 6615-6628.
Read now
Rohit K Jain & Hongbin Chen. (2017) Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer: Targets and Therapy 8, pages 169-177.
Read now

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.